Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immuron Ltd Announces US FDA Clears Another IND For Phase 2 Trial For Immuron’s Imm 124e


Thursday, 7 Nov 2013 05:19pm EST 

Immuron Ltd announced that the United States Food and Drug Administration (US FDA) has cleared an Investigational New Drug (IND) submission to commence a clinical trial of IMM 124E, a bovine colostrum derived therapeutic, for the treatment of Alcoholic Steatohepatitis (ASH). NASH and ASH each arise from different causes, and both result in liver damage that can progress to liver fibrosis, liver cirrhosis and lead to of hepatic carcinoma. For this reason, the ASH trial is expected to provide Immuron with additional guidance on its impending NASH trials for which a IND was cleared as announced on January 10, 2012. Immuron is expecting to deliver its Investigational Medicinal Product imminently for commencement of the trial. 

Company Quote

0.0060
-0.0010 -14.29%
29 Aug 2014